Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SETD7 | Q8WTS6 | 5/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 5/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 5/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 5/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 4/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.76 |
| ▸ | HTR2A | P28223 | 4/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pimethixene SCHEMBL29433731 | 1.00 | SETD7 (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11432245 | 0.87 | HTR1A (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Pimethixene SCHEMBL301225 | 0.87 | HTT (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11573964 | 0.87 | KCNH2 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11574284 | 0.87 | SETD7 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11573081 | 0.87 | SETD7 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| Pimethixene SCHEMBL301226 | 0.87 | HTT (1.00) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11575971 | 0.87 | SETD7 (0.76) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11600806 | 0.85 | DRD3 (0.73) | SETD7CHRM2CHRM1ADRA1AKCNH2 | |
| SCHEMBL11431794 | 0.85 | SETD7 (0.72) | SETD7CHRM2CHRM1ADRA1AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 450 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | UNIVERSITY OF CINCINNATI (US) | 2026-02-17 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| WO-2024163699-A1 | SELECTIVE FIASMA TREATMENT | VALO HEALTH, INC. (US) | 2024-08-08 | — | — | WO | claimed |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2023-10-12 | — | — | US | claimed |
| EP-4171545-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE HOPITAUX DE PARIS (FR) | 2023-05-03 | — | — | EP | claimed |
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BIOPHAGY INC (US) | 2022-03-10 | — | — | US | claimed |
| WO-2021260152-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) | 2021-12-30 | — | — | WO | claimed |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BIOPHAGY INC (US) | 2021-12-28 | — | — | US | claimed |
| US-20210235686-A1 | RED BLOOD CELL STORAGE SOLUTIONS, SOLUTION ADDITIVES, AND METHODS FOR IMPROVING THE STORAGE OF RED BLOOD CELLS | UNIVERSITY OF CINCINNATI | 2021-08-05 | — | — | US | claimed |
| US-10736910-B2 | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits | STC.UNM (US) | 2020-08-11 | — | — | US | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007026151-A1 | ANTIHISTAMINE- AND CORTICOSTEROID- CONTAINING LIPOSOME COMPOSITION AND ITS USE FOR THE MANUFACTURE OF A MEDICAMENT FOR TREATING RHINITIS AND RELATED DISORDERS | BIOLIPOX AB (SE) | 2007-03-08 | — | — | WO | claimed |
| WO-2006131737-A2 | METHOD AND COMPOSITION FOR TREATING INFLAMMATORY DISORDERS | BIOLIPOX AB (SE) | 2006-12-14 | — | — | WO | claimed |
| EP-1641446-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | Pediamed Pharmaceuticals, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1151295-A4 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | CYTOVIA INC (US) | 2005-03-30 | — | — | EP | claimed |
| US-20050059656-A1 | Compositions and methods for protecting against mitochondria component-mediated pathology | CORNELL RESEARCH FOUNDATION, INC. | 2005-03-17 | — | — | US | claimed |
| WO-2004112771-A1 | PHARMACEUTICAL COMPOSITIONS INCLUDING AN ANTIHISTAMINE AND A STIMULANT AND USE THEREOF | PEDIAMED PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| US-20040259809-A1 | Pharmaceutical compositions including an antihistamine and a stimulant and method of use thereof | PEDIAMED PHARMACEUTICALS, INC. | 2004-12-23 | — | — | US | claimed |
| EP-1151295-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | Cytovia, Inc. (US) | 2001-11-07 | — | — | EP | claimed |
| WO-2000045165-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12550885-B2 | Red blood cell storage solutions, solution additives, and methods for improving the storage of red blood cells | SMPD3, SMPD4, CMA1 | SETD7 1789/4885CHRM2 100/4885CHRM1 246/4885 |
| US-20230321008-A1 | INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE | SMPD2, SMPD1, SMPD3 | SETD7 2912/4885CHRM2 1663/4885CHRM1 1851/4885 |
| US-11208371-B2 | Compounds, compositions, and methods for use in treating autophagy-associated disorders | BECN1, ATG7, SQSTM1 | SETD7 4670/4885CHRM2 3916/4885CHRM1 4294/4885 |
| US-20220073444-A1 | Compounds, Compositions, and Methods for use in Treating Autophagy-Associated Disorders | BECN1, ATG7, SQSTM1 | SETD7 4670/4885CHRM2 3916/4885CHRM1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.